Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    remdesivir expanded | covid 19
Previous Study | Return to List | Next Study

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04323761
Expanded Access Status : Approved for marketing
First Posted : March 27, 2020
Last Update Posted : November 13, 2020
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences

Tracking Information
First Submitted Date March 24, 2020
First Posted Date March 27, 2020
Last Update Posted Date November 13, 2020
 
Descriptive Information
Brief Title Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
Brief Summary The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Treatment IND/Protocol
Intervention Drug: Remdesivir
Intravenous infusion administered over a 30 to 120 minute period
Other Names:
  • GS-5734™
  • Veklury®
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status Approved for marketing
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Australia,   Austria,   Belgium,   Canada,   Cyprus,   Czechia,   Denmark,   Estonia,   France,   Germany,   Greece,   Hungary,   Iceland,   Ireland,   Israel,   Italy,   Lithuania,   Netherlands,   Poland,   Portugal,   Romania,   Slovakia,   Slovenia,   Spain,   Switzerland,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT04323761
Responsible Party Gilead Sciences
Study Sponsor Gilead Sciences
Collaborators Not Provided
Investigators
Study Director: Gilead Study Director Gilead Sciences
PRS Account Gilead Sciences
Verification Date November 2020